HS-20110 with bevacizumab and chemotherapy for advanced colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label Phase Ib/II study using a Rolling 6 dose-escalation design to find the recommended phase II dose (RP2D) of HS-20110 given with bevacizumab and standard chemotherapy backbones. Three cohorts combine HS-20110 with bevacizumab plus 5-FU/leucovorin, bevacizumab plus oxaliplatin and 5-FU/leucovorin, or bevacizumab plus oxaliplatin and capecitabine. After the RP2D is identified in Phase Ib, a Phase II expansion will further test safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with metastatic colorectal cancer. The study enrolls adults with pathologically confirmed colorectal cancer who are non-MSI-H and without BRAF V600E mutation and requires at least one measurable lesion per RECIST 1.1.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males or females, aged ≥ 18 years.
* Participants with pathologically confirmed advanced Colorectal Cancer.
* Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1.
* MSI was tested to be non-MSI-H, and without BRAF V600E mutation.

Exclusion Criteria:

* Participants have received or are receiving the following treatment:

  1. Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.
  2. Local radiotherapy within 2 weeks prior to the first dose of study treatment; irradiation of more than 30% of bone marrow or extensive radiotherapy within 4 weeks prior to the first dose of study treatment.
  3. Major surgery within 4 weeks prior to the first dose of study treatment.
  4. Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.
  5. Current use of drugs known to prolong the QT interval or that may cause torsade de pointes. Participants who need to receive these drugs during the study period should also be excluded.
  6. Live vaccine or live-attenuated vaccine within 28 weeks prior to the first dose.
* Participants who have any Grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior therapies (except alopecia and residual neurotoxicity).
* Inadequate bone marrow reserve or hepatic and renal functions.
* Participants with a history of severe allergy (such as anaphylactic shock), previous severe infusion reactions, or allergy to recombinant human or murine proteins.
* Participants who are allergic to any component of HS-20110 combination therapies.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• Urine test to help spot colorectal cancer and polyps

  This study tests a urine-based 3-metabolite biosensor to see if it can detect colorectal cancer and precancerous polyps in adults in Ghana, Tanzania, and South Africa.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 3 other locations · NCT07649057

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• CBI-1214 T-cell engager for advanced MSS/MSI-L colorectal cancer

  This trial will test whether the experimental T-cell engager CBI-1214 is safe, reaches appropriate blood levels, and can shrink tumors in people with advanced or metastatic MSS/MSI-L colorectal cancer who have had prior treatment.

  Recruiting at 10 sites Phase 1 Cartography Biosciences · Phoenix, Arizona and 9 other locations · NCT07321106

• HCB101 combined with cetuximab or bevacizumab plus FOLFOX/FOLFIRI for advanced metastatic colorectal cancer

  This trial tries weekly HCB101 infusions together with cetuximab or bevacizumab and FOLFOX or FOLFIRI chemotherapy in adults with advanced or metastatic RAS/BRAF wild-type colorectal cancer who have progressed after prior chemotherapy.

  Recruiting Phase 1/2 Chang Gung Memorial Hospital · Taoyuan · NCT07204574

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.